Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2010

01-01-2010 | Review Article

Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials

Authors: Loukia S. Poulou, Loukas Thanos, Panayiotis D. Ziakas

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2010

Login to get access

Abstract

Purpose

The predictive value of 18F-FDG PET in patients with relapsing/refractory lymphoma who are receiving high-dose chemotherapy and autologous stem cell transplantation (ASCT) remains a matter of debate. Seminal reports on pretransplant ASCT indicated an adverse prognosis in patients with positive FDG PET scans. The lack of a uniform outcome measure along with the mixed histologies in various studies have hampered efforts to quantify this prognostic value.

Methods

A MEDLINE review of published trials up to April 2009 identified 16 studies involving pretransplant FDG PET scans in lymphoma. Where progression-free survival (PFS) and overall survival (OS) were set as the main outcome measures, time-to-event data analysis was used to calculate the overall prognostic value of a pretransplant FDG-PET scan.

Results

Pooled survival data from seven eligible studies suggested a worse PFS in patients with a positive FDG PET study (HR 3.23, 95% CI 2.14 to 4.87). The OS pooled from six eligible studies was also significantly worse among patients with a positive FDG PET study (HR 4.53, 95% CI 2.50 to 8.22). No statistically significant heterogeneity was observed between studies for either outcome.

Conclusion

Despite the documented clinical heterogeneity between studies, meta-analysis data confirmed the prognostic impact of pretransplant FDG PET in patients with lymphoma and provided a uniform measure of the association for both progression and survival after ASCT.
Literature
1.
Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066–74.CrossRefPubMed
2.
Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006;91:522–9.PubMed
3.
Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: a systematic review. J Nucl Med. 2008;49:13–21.CrossRefPubMed
4.
Poulou LS, Karianakis G, Ziakas PD. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin’s disease. Eur J Radiol. 2009;70:499–506.CrossRefPubMed
5.
Ziakas PD, Poulou LS. Improving outcome after positive interim PET in advanced Hodgkin’s disease: reality vs expectation. Eur J Nucl Med Mol Imaging. 2008;35:1573–5.CrossRefPubMed
6.
Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260–7.CrossRefPubMed
7.
Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2002;30:103–11.CrossRefPubMed
8.
Johnston PB, Wiseman GA, Micallef IN. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41:919–25.CrossRefPubMed
9.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
10.
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.CrossRefPubMed
11.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.CrossRefPubMed
12.
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53–9.CrossRefPubMed
13.
Filmont JE, Czernin J, Yap C, et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003;124:608–13.CrossRefPubMed
14.
Schot B, van Imhoff G, Pruim J, et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol. 2003;123:282–7.CrossRefPubMed
15.
Schot BW, Pruim J, van Imhoff GW, et al. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006;91:490–5.PubMed
16.
Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:211–6.CrossRefPubMed
17.
Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–91.CrossRefPubMed
18.
Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:2481–9.CrossRefPubMed
19.
Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110:1361–9.CrossRefPubMed
20.
Bishu S, Quigley JM, Schmitz J, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007;48:1531–8.CrossRefPubMed
21.
Yoshimi A, Izutsu K, Takahashi M, et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol. 2008;83:477–81.CrossRefPubMed
22.
Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008;49:727–33.CrossRefPubMed
23.
Alousi AM, Saliba RM, Okoroji GJ, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008;142:786–92.CrossRefPubMed
24.
Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:2496–503.CrossRefPubMed
25.
Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2009;43:941–8.CrossRefPubMed
26.
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlledtrials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896–900.CrossRefPubMed
27.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRef
Metadata
Title
Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials
Authors
Loukia S. Poulou
Loukas Thanos
Panayiotis D. Ziakas
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1258-y

Other articles of this Issue 1/2010

European Journal of Nuclear Medicine and Molecular Imaging 1/2010 Go to the issue

Original Article

Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study

Original Article

PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[18F]F-L-DOPA

Original Article

Nuclisome: a novel concept for radionuclide therapy using targeting liposomes

Original Article

Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation

Original Article

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab

Book Review

C. B. Benson and E. I. Bluth, Ultrasonography in obstetrics and gynecology. A practical approach, 2nd edition